PPARG single gene test
Methodology
Molecular
Test Description and clinical significance
Genes
PPARG
Disease:
Bladder urothelial carcinoma, cutaneous melanoma, lung adenocarcinoma, melanoma, and endometrial endometrioid adenocarcinoma
Molecular test that utilizes NGS technology to detect mutations in PPARG. This gene encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPAR-gamma. The protein encoded by this gene is PPAR-gamma and is a regulator of adipocyte differentiation.
Specimen Requirements
Collection:
FFPE sections, 5-10 sections are recommended at 4 to 10 micron. A minimum of 20 ?l of RNA with a concentration of at least 5ng/?l and an OD260/280 ratio of 2.0-2.1 respectively, obtained on a spectrophotometer is required.
Stability:
FFPE blocks- Indefinitely/ FFPE Slides-4 weeks
Unacceptable Conditions:
Specimen submitted is in the incorrect fixative. Insufficient specimen (less than 10% of tumor). Unlabeled or improperly labeled specimens. Decalcified specimens. Improperly stored RNA.
Storage & Transport
Store FFPE blocks and slides at room temperature. Genomic RNA must be stored at –60 to –85°C.
CPT(s)
81401, 81479
New York Approved
NO
TAT
10 Days
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
